Linda Wernevik

An oral antisense oligonucleotide for PCSK9 inhibition

Peter Gennemark, Katrin Walter, Niclas Clemmensen et al. · Science Translational Medicine · 2021 · 121 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials

Javier Armisen, Mitra Rauschecker, Janeli Sarv et al. · Journal of Hepatology · 2025 · 53 citations

Life Sciences, Genetics, Molecular Genetics +4

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

Fredrik Erlandsson, Muna Albayaty, Ligia Chialda et al. · British Journal of Clinical Pharmacology · 2018 · 28 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

Andrew K. Whittaker, Judith Hartleib‐Geschwindner, Muna Albayaty et al. · Clinical and Translational Science · 2019 · 27 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA

Michael J. Koren, Alexis Hofherr, Jennifer Schumi et al. · Journal of the American College of Cardiology · 2022 · 18 citations

Pharmacy, Pharmacology, Pharmacotherapy +13